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要旨 
 
【背景】受容体活性調節蛋白１（RAMP1）は、カルシトニン受容体様受容体（CLR）とヘテロダイ
マーを形成し、カルシトニン遺伝子関連ペプチド（CGRP）受容体を形成している。CGRP は 37 個
のアミノ酸からなるポリペプチドであり、主に神経系に幅広く発現し、多様な生理作用が知られ
ている。分子薬理研究室では、これまでにさまざまなモデルを用いて CGRPが血管新生に関与して
いるということを報告してきた。本研究では RAMP1 に着目し、創傷の治癒過程および創傷部位の
脈管新生における CGRP−RAMP1シグナルの役割について検討を行った。 
 
【方法】8 週齢の野生型 C57BL/6 雄性マウス（WT）および RAMP1-/-を使用し、創傷治癒モデルを
作成した。マウス背部の皮膚に直径 6mm の創を作成し、WT と RAMP1-/-とで治癒経過を比較した。
また創傷肉芽組織を対象として、免疫組織化学的評価や real time PCR を行い、脈管新生の評価
を行った。 
 
【結果および考察】WT に比べ RAMP1-/-では、早期における創傷治癒の遅延が認められた。また、
肉芽組織における血管内皮マーカーCD31の免疫染色では、RAMP1-/-で血管密度が有意に抑制され
た。また real-time PCR を行い、肉芽組織における CD31 と血管新生増強因子 VEGF-A の発現量を
調べたところ、いずれも治癒早期の段階で RAMP1-/-において発現の抑制が認められた。これらの
結果から、創傷部の肉芽組織における VEGF-A を介した血管新生に CGRP-RAMP1 シグナルが関与し
ていることが示唆された。 
 
次に、抗 RAMP1抗体および抗 CD31抗体を用いて免疫染色を行い、血管における RAMP1の局在につ
いて評価したところ、創周辺部の健常皮膚組織の血管上には RAMP1 の発現が認められたが、肉芽
組織内の新生血管上には RAMP1の発現が認められなかった。この結果から、CGRP-RAMP1シグナル
は血管新生には関与するものの、新生血管の内皮細胞には直接的に作用していない可能性が考え
られた。 
 
そこで、肉芽の主要構成細胞である線維芽細胞とマクロファージに着目し、それぞれの細胞上に
RAMP1が発現しているか検討を行った。繊維芽細胞に対しては抗 S100A4抗体、マクロファージに
対しては抗 CD11b 抗体を用いて、抗 RAMP1 抗体との二重染色を行ったところ、それぞれ共発現部
位が観察されたことから、線維芽細胞とマクロファージの表面に RAMP1 が発現していることが分
かった。 
 
そこで次に in vitro の検討として、線維芽細胞とマクロファージを CGRP アゴニストで刺激し、
VEGF-Aの遺伝子発現量の変化を評価した。その結果、繊維芽細胞の細胞株である L929では VEGF-A
の発現は減少したが、マクロファージでは VEGF-Aの発現が用量依存的に増加した。この結果から、
マクロファージ上の RAMP1 が CGRP の刺激を受けて、VEGF-A の産生を促進し、血管新生を誘導し
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ていることが示唆された。 
また同実験において、リンパ管新生増強因子 VEGF-C および VEGF-D の遺伝子発現量の変化につい
ても評価した。その結果、L929では VEGF-C・VEGF-Dいずれも発現量に変化は認められなかった。
一方マクロファージでは、VEGF-Dの発現量に変化は認められなかったが、VEGF-Cの発現は用量依
存的に増加した。この結果から、マクロファージが CGRP の刺激を受けて、VEGF-C の産生を促進
し、リンパ管新生も誘導している可能性が考えられた。 
 
そこで、肉芽組織におけるリンパ管内皮マーカーLYVE-1の免疫染色を行い、リンパ管新生を評価
してみると、RAMP1-/-でリンパ管密度が有意に抑制された。また real-time PCR を行い、肉芽組
織における VEGF-Cとリンパ管内皮マーカーVEGFR-3の発現量を調べたところ、いずれも治癒早期
から中期にかけて RAMP1-/-において発現の抑制が認められた。さらに、創作成後 7日目のマウス
の創直下に FITC デキストランを投与し、新生リンパ管のドレナージ機能を評価したところ、
RAMP1-/-ではリンパ管新生の抑制に伴いドレナージ機能が有意に抑制された。これらの結果から、
創傷部の肉芽組織における VEGF-C を介したリンパ管新生に CGRP-RAMP1 シグナルが関与している
ことが示唆された。 
 
次に、創傷肉芽組織のマクロファージは骨髄から動員されてくることが知られているため、骨髄
移植モデルを作成し、骨髄由来マクロファージが創傷部へ動員され治癒を促進しうるかどうか、
また動員された際の CGRP−RAMP1シグナルの役割について検討を行った。 
WT の骨髄を移植したマウスと RAMP1-/-の骨髄を移植したマウスとで創傷治癒経過を比較すると、
RAMP1-/-骨髄移植マウスでは、早期における創傷治癒の遅延が認められた。 
また肉芽組織の免疫染色では、RAMP1-/-骨髄移植マウスにおいて血管密度・リンパ管密度が有意
に抑制された。これらの結果から、創傷治癒時の肉芽組織では、骨髄から動員されたマクロファ
ージが CGRP の刺激を受け、VEGF-A、VEGF-C の産生を介して血管新生・リンパ管新生を増強させ
ることが明らかとなった。 
 
【結論】今回の実験から、創傷治癒過程における脈管新生には、CGRP-RAMP1シグナル伝達による
VEGF 誘導の重要性が示唆された。RAMP1 は血管新生やリンパ管新生がかかわる疾患の治療標的と
して重要であると考えられる。 
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1. Introduction 
 
Calcitonin gene-related peptide (CGRP) is a 37-aa neuropeptide that is produced in the 
neural body of dorsal root ganglion (DRG) cells and released from sensory nerve 
endings. Receptor activity-modifying proteins (RAMPs) are a family of proteins that 
interact with and modulate the activities of several class B G-protein-coupled receptors 
(GPCRs). The RAMP protein family consists of 3 members, RAMP1, RAMP2, and 
RAMP3, each of which is encoded by a separate gene and has diverse spatiotemporal 
expression patterns (1). CGRP binds to CGRP receptors composed of RAMP1 and 
calcitonin receptor-like receptor (CLR) to modulate various functions, such as 
vasodilation and pain transmission (2, 3). CGRP couples to the activation of adenylate 
cyclase (AC) to elevate cAMP levels; however, biochemical and pharmacologic studies in 
cultured cells show that RAMPs can modulate additional aspects of CGRP receptor 
signaling, including receptor trafficking, ligand binding affinity, second-messenger 
signaling and receptor desensitization. Several gene-targeted knockout and transgenic 
models have been generated and characterized in recent years (4).  
CLR is a common receptor subunit for both CGRP and adrenomedullin (AM), a 52-aa 
peptide that shares some degree of homology with CGRP (5). The specificity of the 
CGRP receptor is believed to be decided by RAMP1, in light of the finding that the N 
terminus of RAMP1 is essential for CGRP binding (6). To elucidate the physiological 
functions of CGRP mediated through CLR/RAMP1 receptors in vivo, we generated 
RAMP1-deficient (RAMP1-/-) mice by using a conditional gene-targeting technique. We 
discovered that these mice exhibit potent hypertension, but their heart rate is 
unaffected (7). In addition, the RAMP1-/- mice exhibit a significant increase in serum 
CGRP levels and markedly higher serum levels of proinflammatory cytokines after LPS 
administration, compared with their wild-type (WT) counterparts. Dysregulation of 
proinflammatory cytokine levels in RAMP1-/- mice is attributed to deficient signal 
transduction by CGRP in dendritic cells, suggesting that CLR/RAMP1 receptors 
regulate not only blood pressure but also inflammatory responses.  
We have reported (8-10) that gastrointestinal tracts contain a large amount of CGRP 
and experience the protective actions from the effects of ethanol, a harmful necrotizing 
agent. Recently, we found that CGRP also exhibits proangiogenic activity in models of 
cancer and hindlimb ischemia (11, 12). These studies suggested that CGRP functions as 
an intermediate between vascular and neuronal systems under pathological conditions. 
Further, we identified increased levels of CGRP during gastric ulcer healing that 
facilitate angiogenesis (13).  
The establishment of a vascular supply is essential, not only for organ development and 
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differentiation during embryogenesis, but also for the process of wound healing (14). 
The formation of lymphatic vessels, or lymphangiogenesis, occurs during the 
development of the corpus luteum and during wound healing and may be increased in 
certain pathologic processes (15). It typically occurs at sites of inflammation induced by 
factors produced by macrophages. The process of lymphangiogenesis contributes to the 
reduction of tissue edema and activation of immune responses by facilitating fluid 
drainage and the transport of dendritic cells and macrophages (16-18). In the present 
study, we used RAMP1-/- mice to investigate the role of RAMP1 in lymphangiogenesis 
during the healing of skin wounds. The results showed that CLR/RAMP1 signaling 
plays a crucial role in wound healing and wound-induced angiogenesis and 
lymphangiogenesis and that it presents a promising target for controlling these 
processes in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-3- 
 
2. Materials and Methods 
 
2-1. Animals 
 
RAMP1-/- mice were developed as described elsewhere (7). Male 8- to 10-week-old 
C57BL/6 WT mice and RAMP1-/- mice were used in this study. RAMP1-/- mice exhibit 
good health, show normal behavior, and have no visible phenotypes different from 
normal mice. All animals were housed individually under a 12-h light-dark cycle at a 
constant temperature (25 ± 1°C) and humidity (60 ± 5%). All mice had free access to tap 
water and rodent chow. All experiments were performed in accordance with the 
guidelines for animal experiments established by the Kitasato University School of 
Medicine.  
 
2-2.  Determination of expressions of pro-CGRP, CGRP, and RAMP1 in DRGs  
 
The medulla spinalis was removed, and the DRGs of the L1–5 vertebrae were isolated. 
DRG tissues were homogenized in 1 ml of TRIzol reagent (Gibco-BRL; Life Technologies, 
Rockville, MD, USA). A sample of RNA was extracted from the tissue according to the 
manufacturer's instructions. Real-time PCR was performed as described below. The 
oligonucleotide primers were as follows: for pro-CGRP,  
5′-CCCCAGAATGAAGGTTACACA-3′ (sense) and  
5′-TGTCAAAGGGAGAAGGGTTTT-3′ (antisense); for CGRP, 
5′-CCCCAGAATGAAGGTTACACA-3′ (sense) and  
5′-TGTCAAAGGGAGAAGGGTTTT-3′ (antisense); and for GAPDH, 
5′-CCCTTCATTGACCTCAACTACAATGGT-3′ (sense) and 
5′-GAGGGGCCATCCACAGTCTTCTG-3′ (antisense). 
 
2-3. Skin wound model and evaluation of the wound healing process 
 
Surgical wounds were made on the backs of the mice, as described elsewhere (19). In 
brief, after the mice were anesthetized with pentobarbital sodium (50 mg/kg, i.p.), the 
dorsal hair was shaved, the exposed skin was cleaned with 70% ethanol, and 
full-thickness skin wounds of 6-mm diameter were made aseptically on either side of 
the dorsal midline. The day of surgical treatment was defined as day 0. Each wound 
region was digitally photographed at a fixed time, and the wound areas were calculated 
by Image J image analysis software (U.S. National Institutes of Health, Bethesda, MD, 
USA). Changes in wound area were expressed as a percentage of the wound area at day 
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0. 
 
2-4. Immunohistochemistry 
 
For immunohistochemistry, wound tissues were immediately fixed with 4% 
paraformaldehyde and stained with anti-CD31 antibody (1:500 dilution) and 
anti-lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1; 1:500 dilution), to 
identify blood and lymphatic vessels, respectively. Immune complexes were detected 
with an LSAB + System-HRP kit (DakoCytomation, Carpinteria, CA, USA). 
Wound-induced angiogenesis and lymphangiogenesis in granulation tissues were 
estimated by micro blood vessel density and lymphatic vessel density and expressed as 
the number of vessels per square millimeter.  
For immunofluorescence, the primary antibodies used were anti-RAMP1 antibody 
(1:100 dilution), CD31 (1:500 dilution), CD11b (1:200 dilution), and S100A4 (1:200 
dilution). Images were captured with a confocal scanning laser microscope (LSM700; 
Zeiss, Jena, Germany), and computer-assisted morphometric analyses were performed 
with ZEN 2008 software (Zeiss). 
 
2-5. Collection and culture of peritoneal macrophages  
 
Peritoneal macrophages were obtained from 8- to 10-week-old WT mice and RAMP1-/- 
mice that had received 2 ml of thioglycolate i.p. 3 days earlier. The macrophages were 
washed, resuspended, placed in 12-well culture plates (1 × 106/well), and treated for 24 
h in RPMI 1640 medium (Cambrex, Baltimore, MD, USA), containing 10% FBS at 37°C 
in 5% humidified CO2. After 24 h, the plates were washed with phosphate-buffered 
saline (PBS) to remove nonadherent cells. Approximately 60% of the cells remained 
adherent and were used in all subsequent experiments. 
 
2-6. Real-time RT-PCR 
 
Transcripts encoding CD31, vascular endothelial growth factor (VEGF)-A, VEGF-C, 
VEGFR-3, epidermal growth factor (EGF), transforming growth factor (TGF)-β, basic 
fibroblast growth factor (bFGF), connective tissue growth factor (CTGF), and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were quantified by real-time 
RT-PCR analysis. Total RNA was extracted from mouse tissues with TRIzol 
(Gibco-BRL), and single-stranded cDNA was generated from 1 μg of total RNA via 
reverse transcription with ReverTra Ace-α (Toyobo, NewYork, NY, USA). Quantitative 
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PCR amplification was performed with SYBR Premix Ex Taq (Takara Bio, Shiga, 
Japan) and the following gene-specific primers: 
5’-ACTTCTGAACTCCAACAGCGA-3’ (sense) and 
5’-CCATGTTCTGGGGGTCTTTAT-3’ (anti-sense) for CD31, 
5’-GAGAGAGGCCGAAGTCCTTT-3’ (sense) and 
5’-TTGGAACCGGCATCTTTATC-3’ (anti-sense) for VEGF-A, 
5’-TCTGTGTCCAGCGTAGATGAG-3’ (sense) and 
5’-GTCCCCTGTCCTGGTATTGAG-3’ (anti-sense) for VEGF-C, 
5’-CCTATTGACATGCTGTGGGAT-3’ (sense) and 
5’-GTGGGTTCCTGGAGGTAAGAG-3’ (anti-sense) for VEGF-D, 
5’-TTTATGTCCCACCCCCACTAC-3’ (sense) and 
5’-GGCTGAGCTACAAGGCAATCG-3’ (anti-sense) for VEGFR-3, 
5′-ATGGGAAACAATGTCACGAAC-3′ (sense) and 
5′-TGTATTCCGTCTCCTTGGTTC-3′(anti-sense) for EGF,  
5′-AACAATTCCTGGCGTTACCTT-3′ (sense) and 
5′-TGTATTCCGTCTCCTTGGTTC-3′ (anti-sense) for TGF-β, 
5′-GGCTGCTGGCTTCTAAGTGTG-3′ (sense) and  
5′-TTCCGTGACCGGTAAGTATTG-3′(anti-sense) for bFGF, 
5′-AACCGGGGAGGGAAATTATAG-3′ (sense) and 
5′-TGGAATCAGAATGGTCAGAGG-3′ (anti-sense) for CTGF, 
5’-ACATCAAGAAGGTGGTGAAGC-3’ (sense) and 
5’-AAGGTGGAAGAGTGGGAGTTG-3’ (anti-sense) for GAPDH. The obtained threshold 
cycle (Ct) values were processed for further calculations according to the comparative Ct 
method. Expression levels of target genes were normalized to the housekeeping gene 
GAPDH, giving the ΔCt value. Finally, the gene expression level was calculated as 2-ΔCt, 
giving the final value that was normalized to that of the housekeeping gene. 
 
2-7. RT-PCR analysis in macrophages 
 
Thioglycolate-induced macrophages were incubated for 4 h with CGRP (3 and 30 nM) 
and RPMI 1640 medium. Next, the macrophages were collected, and mRNA was 
isolated with Trizol reagent (Life Technologies-Invitrogen, Carlsbad, CA, USA). 
Expression levels of VEGF-A and VEGF-C mRNA in macrophages were measured by 
real-time RT-PCR. 
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2-8. RT-PCR analysis in fibroblasts  
 
Murine fibroblasts (L929) were obtained from the Cell Bank, RIKEN Bioresource 
Center (Ibaraki, Japan). The cells were cultured in DMEM supplemented with 10% 
(v/v) FBS and 100 U/500 ml penicillin (GIBCO-BRL) at 37°C in 5% humidified CO2. 
L929 fibroblasts (3×105 cells/well) were incubated for 6 h with CGRP (3 and 30 nM) and 
PBS, and the mRNA expression levels of VEGF-A, VEGF-C and VEGF-D in fibroblasts 
were determined by real-time RT-PCR.  
 
2-9. Drainage of fluorescein isothiocyanate–dextran from wound areas 
 
At 7 days after wounding, 200 μl of 3% fluorescein isothiocyanate–dextran was injected 
s.c. into the wound granulation tissues. At 2 h after the injections, axillary lymph nodes 
were excised to measure the intensity of fluorescence drained from the wound area via 
newly formed lymphatic vessels. A Nano Drop 3300 Fluorospectrometer (Thermo 
Scientific, Wilmington, DE, USA) was used to quantitate the intensity of the 
fluorescence of the extracted dye.  
 
2-10. Murine bone marrow transplantation (BMT) model 
 
Bone marrow (BM) cells were obtained by flushing the cavities of freshly dissected 
femurs and tibiae from donor male RAMP1-/- mice with PBS. Donor BM cells were 
harvested from their WT counterparts (8-week-old male C57BL/6 mice) by the same 
method. The flushed BM cells of each donor were dispersed by pipetting and 
resuspended in PBS at a density of 1×107 cells/ml. WT mice were lethally irradiated at 
9.0 Gy, with an MBR-1505R X-ray irradiator (Hitachi Medico Co., Tokyo, Japan) with a 
filter (copper, 0.5 mm; aluminum, 2 mm) monitoring the cumulative radiation dose. 
Donor BM mononuclear cells (2×106 cells) in 200 μl of PBS were transplanted via the 
tail vein of irradiated WT mice. After 12 weeks, peripheral blood was collected, and 
RAMP1 expression was tested to confirm chimerism.  
GFP transgenic mice (a gift from Dr. M. Okabe, Genome Information Research Center, 
Osaka University, Osaka, Japan) with a C57BL/6 background were used as WT mice to 
confirm the chimerism. The mice, in which >95% of the peripheral leukocytes exhibited 
GFP positivity in fluorescence-activated cell-sorting analysis, were used in this 
experiment as the control group. 
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2-11. Denervation of sciatic nerves  
 
Unilateral denervation of the sciatic nerve was performed in mice under pentobarbital 
sodium anesthesia (25 mg/kg). The sciatic nerves (L1-5) were exposed through a gluteus 
muscle incision, and 5 mm of the sciatic nerve distal to the DRG was removed. The 
operated region was marked with a polypropylene suture (6-0; Ethicon) with the aid of 
an operating microscope. Sham-operated mice were prepared as controls with the same 
operation but without the sciatic nerve axotomy. After confirming the delay in escape 
from the heat, surgical wounds were made on the backs of hind limb, as described 
previously (11). 
 
2-12. Chemical denervation  
 
Neonatal mice (WT) were given subcutaneously with capsaicin at doses of 50 mg/kg. 
Eight weeks after the capsaicin treatment, wounds were made on the back of the mice, 
and wound healing process was determined as described above. 
 
2-13. Statistical analysis 
 
Data are expressed as means ± SEM. Comparisons among multiple groups were 
performed via factorial analysis of variance (ANOVA), followed by Scheffe’s test. 
Comparisons between 2 groups were performed with the Mann-Whitney U test. Values 
of P < 0.05 were considered statistically significant. 
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3. Results 
 
3-1. Suppression of wound-induced angiogenesis in RAMP1-/- mice 
 
The RAMP1-/- mice appeared healthy, and their small size was the same as that of 
their WT counterparts. The basal levels of mRNAs of pro-CGRP and CGRP in the DRG 
tissues in the non-treated RAMP1-/- mice were not different from those in WT (Fig. 1 A,  
B), suggesting that the CGRP levels in the neuronal system were not reduced in 
RAMP1-/-. By contrast, the RAMP1 expressed in the DRGs was much lower in the 
RAMP1-/- mice in comparison with the WT (Fig. 1C). These results suggest that 
RAMP1-/- mice are good tools for evaluating the CGRP signaling in pathologic 
conditions.  
Full-thickness skin wounds were surgically created on the backs of WT mice, and the 
closure of the wounds was monitored. The healing process observed in this mouse 
model occurred in a manner essentially the same as the process reported previously. At 
24 h after wounding, the wound areas were reduced to 50% in the control WT mice, and 
the wounds were completely closed after 13 days. Invasion of granulation tissue from 
the wound margins into the wound bed was observed 2 days after injury. At day 3, the 
wound bed was filled completely with granulation tissue, and at this stage, marked 
neovascularization was evident.  
To evaluate the roles of endogenous CGRP-RAMP1 signaling in wound-dependent 
angiogenesis and wound closure, we created skin wounds in both RAMP1-/- mice and 
WT mice, and monitored the healing process for 14 days. As shown in Fig. 1D, E, wound 
closure in the RAMP1-/- mice was significantly delayed compared with that in the WT 
mice, especially during the early phase of the healing process.  
At days 2, 3, 4, 5, 6, and 7, we compared the histologic appearance of wounds in the WT 
and RAMP1-/- mice. Although immunostaining of CD31-positive microvessels indicated 
the presence of abundant microvessel assemblies in the wound granulation tissues (Fig. 
2B) of the WT mice, few were observed in the RAMP1-/- mice (Fig. 2B, C). Moreover, the 
RAMP1-/- mice demonstrated significantly lower microvessel densities throughout the 
observation periods than did the WT mice (Fig. 2D). Real-time RT-PCR analysis also 
showed significantly lower CD31 and VEGF-A mRNA levels in the RAMP1-/- mice than 
in the WT mice during the early phase of the healing process (days 2, 5, and 7 for CD31; 
days 2, and 3 for VEGF-A, Fig. 2E, F). When the expressions of other cytokines were 
determined in the wound granulation tissues, TGF-β, bFGF, and CTGF were also 
reduced in the early stage of wound healing in the RAMP1-/- mice, whereas there was 
no marked reduction in EGF (Fig. 6). These results suggest that endogenous 
-9- 
 
CGRP-RAMP1 signaling up-regulates angiogenesis in the wound granulation tissues 
by inducing the growth factors including VEGF-A, and thereby facilitates wound 
healing.  
To examine the localization of RAMP1 in the endothelial cells (ECs), we performed 
double immunostaining of RAMP1 and CD31 (Fig. 2A). No RAMP1/CD31 
double-positive vessels were observed in granulation tissues, although they were 
present in uninjured lesions around the wounds. This observation indicates that newly 
formed vessels in granulation tissues lack RAMP1 expression. These results suggest 
that CGRP-RAMP1 signaling does not play a direct role in forming new vessels.  
 
3-2. Cellular components relevant to CGRP-RAMP1 signaling-dependent angiogenesis 
 
To identify the cells responsible for enhancing wound-induced angiogenesis via 
CGRP-RAMP1 signaling, we evaluated macrophages and fibroblasts, the 2 major 
components of wound granulation tissues. We performed double immunostainings of 
RAMP1 and CD11b, a macrophage marker (Fig. 3A), and of RAMP1 and S100A4, an 
activated fibroblast marker (Fig. 3B) in granulation tissues 7 days after wounding. A 
large number of CD11b- and S100A4-positive cells were found to express RAMP1. We 
then tested the in vitro effects of CGRP on macrophages and fibroblasts. When mouse 
fibroblasts (L929 cells) were treated with CGRP agonists, no increase in VEGF-A 
expression was observed (Fig. 3F). By contrast, VEGF-A expression increased in 
macrophages isolated from the peritoneal cavities of WT mice in a dose-dependent 
manner when treated with CGRP agonists (Fig. 3C). These results suggest that 
CGRP-RAMP1 signaling up-regulates angiogenesis in granulation tissues by inducing 
VEGF-A expression in macrophages.  
Furthermore, we tested whether lymphangiogenic factors increase in response to 
CGRP agonists. Neither VEGF-C nor VEGF-D production was significantly enhanced 
in L929 cells (Fig. 3G, H). In macrophages, VEGF-C expression increased, whereas 
VEGF-D expression did not (Fig. 3D, E). These results suggest that CGRP-RAMP1 
signaling up-regulates lymphangiogenesis in granulation tissues by inducing VEGF-C 
in macrophages, but not in fibroblasts.  
 
3-3. Suppression of wound-induced lymphangiogenesis in RAMP1-/- mice  
 
On days 3, 5, 6, 7, and 10, we compared the histologic appearance of the wounds in the 
WT and RAMP1-/- mice, to evaluate lymphangiogenesis in granulation tissues. 
Immunohistochemical analysis with an antibody to the lymphatic-specific marker 
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LYVE-1 revealed fewer LYVE-1-positive lymphatic structures in the RAMP1-/- mice 
than that in the WT mice (Fig. 4B, C). Moreover, quantitative analysis of lymphatic 
vessel density confirmed that wound-induced lymphangiogenesis in the RAMP1-/- mice 
was significantly reduced at days 6, 7, and 10 compared with that in the WT mice (Fig. 
4D). Real-time RT-PCR analysis also showed significantly lower VEGF-C and 
VEGFR-3 mRNA levels in the RAMP1-/- mice than in the WT mice from early phases of 
the healing process (Fig. 4E, F). These results suggest that lymphangiogenesis in 
wound granulation tissues is accelerated by VEGF-C and VEGFR-3 signaling from 
early stages and is dependent on endogenous CGRP-RAMP1 signaling. In addition, as 
shown in Fig. 4G, H, the drainage of fluorescent dye injected into the wound area into 
the regional lymph nodes (axillary lymph nodes) was reduced in the RAMP1-/- mice at 
day 7, when lymphangiogenesis was suppressed in the mice. Therefore, 
lymphangiogenesis appears to modulate lymphatic flow in the granulation tissues with 
newly formed lymphatic vessels via a CGRP-dependent mechanism.  
To examine the localization of RAMP1 in lymphatic ECs, we performed double 
immunostaining for RAMP1 and LYVE-1 (Fig. 4A). No RAMP1 and LYVE-1 
double-positive vessels were observed in granulation tissues, indicating that newly 
formed lymphatic vessels in granulation tissues do not express RAMP1. These results 
suggest that CGRP-RAMP1 signaling does not directly affect newly formed lymphatic 
vessels, rather, it up-regulates lymphangiogenesis by inducing VEGF-C expression in 
macrophages.  
 
3-4. Role of recruited BM cells expressing RAMP1 in wound healing 
 
Recent results suggest that recruitment of hematopoietic cells from the BM plays a 
crucial role in wound healing. We next examined the role of recruited BM cells 
expressing RAMP1 in wound-induced angiogenesis and lymphangiogenesis. In 
comparison with mice with transplanted WT BM cells, mice with BM cells transplanted 
from RAMP1-/- mice demonstrated significantly delayed wound healing, especially 
during the early phase of the healing process (Fig. 5A). A reduced accumulation of 
RAMP1-postive cells was observed at day 7 after wounding in the wound granulation 
tissues of mice with BM cells transplanted from RAMP1-/- mice (Fig. 7A, B). 
Immunohistochemical analysis with a CD31 antibody showed that microvessel density 
at day 3 after wounding in mice with BM cells transplanted from RAMP1-/- mice was 
significantly suppressed compared with mice receiving WT BM cells (Fig. 5B, C). 
Immunohistochemical analysis with a LYVE-1 antibody revealed significantly 
decreased lymphatic vessel density at day 7 after wounding in mice with BM cells 
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transplanted from RAMP1-/- mice, compared with mice receiving WT BM cells (Fig. 5D, 
E).  
Histologically, GFP-positive cells accumulated in the wound granulation tissues in the 
wound granulation tissues in the WT mice with BM cells transplanted from GFP- 
transgenic mice with a C57BL/6 background, suggesting that transplanted BM cells 
were recruited into the wound granulation tissues. When we performed 
immunostaining of RAMP1, CD11b, and S100A4 in the granulation tissues of mice with 
BM cells transplanted from GFP-transgenic mice 7 days after wounding, a large 
number of GFP and RAMP1 double-positive cells and GFP and CD11b double-positive 
cells were observed in the tissues (Fig. 7C, D). These results suggest that macrophages 
from the BM are recruited into inflammatory lesions, where they appear to secrete 
VEGF-A and VEGF-C in response to CGRP stimulation, thereby contributing to 
angiogenesis and lymphangiogenesis.  
In separate experiments, we confirmed that neuronal system-derived CGRP was 
relevant to RAMP1 stimulation during the healing process of this model. The wound 
healing processes and angiogenesis/lymphangiogenesis in WT mice denervated either 
surgically or chemically, in which CGRP release to the peripheral tissues may be 
reduced, were suppressed in comparison with those in sham-surgery mice and vehicle- 
treated mice (Fig. 8A-E). These strengthen the significance of RAMP1 signaling in the 
wound healing processes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-12- 
 
4. Discussion 
 
CGRP is a 37-aa neuropeptide released in response to sensory stimuli that contributes 
to various biological processes, such as cardiovascular regulation and vasodilation (20). 
Using the peptidic antagonist CGRP (8–37) and the antagonist BIBN4096BS, 
pharmacologic researchers have classified CGRP receptors into 2 subtypes: CGRP-1 
and CGRP-2 (21, 22). Although more CGRP receptor subtypes have been suggested, 
only one receptor, CLR, which belongs to a large family of GPCRs, has been identified 
molecularly (23). This receptor of the B-family of GPCRs forms a heterodimer with a 
single transmembrane domain protein, RAMP. Three distinct RAMPs have been cloned 
and been shown to determine the selectivity of the CRLR-receptor for the different 
members of the calcitonin/CGRP family of peptides (24). Co-expression of CLR with 
RAMP1 results in formation of the CGRP receptor, whereas co-expression of CLR with 
RAMP2 or RAMP3 corresponds to the formation of AM1 or AM2 receptors, respectively 
(24). CGRP binds to the AM2 receptor with ～50-fold lower affinity than does AM and 
has an even lower affinity for AM1 receptors (24). This suggests that RAMP1 is the key 
receptor for supporting CGRP activity and that a RAMP1-null mouse model is a good 
tool for clarifying the roles of CGRP and RAMP1 in vivo.  
In the present experiment, we used RAMP1-/- mice to define the roles of RAMP1 in 
angiogenesis and lymphangiogenesis during wound healing. As shown in Fig. 2C-E, 
angiogenesis in the granulation tissues in the base of the wounds was suppressed from 
the early stages in the RAMP1-/- mice in comparison with that in their WT 
counterparts. Expression of RAMP1 in vascular ECs in granulation tissues in the WT 
mice was faint compared with the expression observed in established blood vessels in 
normal mouse skin. The potent hypotensive action of CGRP is explained by the 
stimulation of CGRP receptor in which RAMP1 commits as a cofactor for the 
intracellular signaling.  
The low level of RAMP1 expression in neovascularized blood vessels was a surprising 
observation. It has been frequently reported that microvascular ECs display a large 
degree of functional heterogeneity, depending on their location in the vascular tree (25). 
The existence of organ-specific, microvascular-bed-specific, and even intravascular 
variations in endothelial cell gene expression emphasizes their high cell-to-cell 
variability, which allows them to adapt to changing conditions. Further, the ability of 
microvascular ECs to respond dynamically to pathology-related microenvironmental 
changes is particularly apparent with respect to angiogenesis. The present study 
demonstrates that the site of CGRP activity and the localization of RAMP1 in 
neovascularized areas are different than in vascular ECs. Newly formed blood vessels 
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in a pathologic setting may be quite different from the mature blood vessels formed 
during development and tissue maintenance and homeostasis.  
The major cellular components of wound granulation tissues relevant to healing and 
angiogenesis are fibroblasts and macrophages (19). Both fibroblasts and macrophages 
express RAMP1, but when cultured fibroblasts were incubated with CGRP, no increase 
in the expression of VEGF isoforms was observed (Fig. 3F-H). By contrast, when 
exposed to CGRP, macrophages isolated from the mouse peritoneal cavity exhibited 
increased expression of VEGF-A and VEGF-C, but not VEGF-D, in a dose-dependent 
manner (Fig. 3C-E). VEGF-A is active in this model, since the addition of a VEGF 
neutralizing antibody or VEGF receptor tyrosine kinase inhibitor strongly inhibits 
proangiogenic processes (26). Furthermore, VEGF-C is a potent inducer of 
lymphangiogenesis (27). LYVE-1-positive cells did not express RAMP1, indicating that 
lymphatic ECs do not express RAMP1 in the same manner as neovascularized vascular 
ECs. Newly formed lymphatics also failed to exhibit RAMP1 expression, suggesting 
that the important cellular components are non-ECs, such as macrophages. VEGF-C 
reduction was seen in the RAMP1-/- from the early stages of the healing. Thus, it 
appears that lymphangiogenesis, as seen in the present study, may be regulated by 
VEGF-C released from macrophages in the early stages.  
The established lymphatic vessels observed in this study effectively drained the 
interstitial fluids, as demonstrated by the movement of dye injected subcutaneously 
(Fig. 4G, H). AM induces lymphangiogenesis (28), and the presence of the AM receptor 
on lymphatic ECs is reported, suggesting that the cellular components necessary for 
RAMP1 signaling are different from those needed for AM activity. 
Immunohistochemical staining revealed that RAMP1 expression co-localized with 
CD11b expression, suggesting that macrophages actively induce lymphangiogenesis in 
granulation tissues in the wound base. This is the first report describing the 
involvement of RAMP1 expressed by macrophages in enhancing angiogenesis and 
lymphangiogenesis in vivo. Controlling RAMP1 signaling is a good option for the 
treatment of angiogenesis/lymphangiogenesis-related pathologic conditions. In addition, 
recruited macrophages were shown to be crucial for angiogenesis/lymphangiogenesis, 
since RAMP1-/- BM chimeric mice exhibited decreased angiogenesis and 
lymphangiogenesis in wound granulation tissues and showed delayed wound healing 
(Fig. 5).  
Activation of the CGRP receptor results in Gαs-mediated activation of AC with a 
subsequent increase in cAMP and activation of nitric oxide synthase (NOS), both of 
which are closely related to vasodilatation (29-32). We previously reported that cAMP 
elevation up-regulated the expression of VEGF and enhanced angiogenesis in a sponge 
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implantation model (33). Forskolin, which activates AC, enhanced angiogenesis, and 
the phosphodiesterase inhibitor amrinone, which induces the accumulation of 
intracellular cAMP, increased neovascularization in sponge granulation tissues (33). 
These intracellular signaling cascades have been shown to couple CGRP receptors 
related to physiological responses, such as vasodilatation of blood vessels. This study 
confirmed that CGRP receptor signaling relevant to cAMP elevation increased 
pathologic angiogenesis and is responsible for increasing VEGF expression in 
hematopoietic cells such as macrophages (Fig. 3C, D), consistent with a previous in 
vitro report (34).  
In the present study, we did not measure the amount of CGRP released. However, we 
have characterized the release of CGRP in angiogenic responses under pathologic 
conditions in previous reports (8, 11-13). Healing of skin wounds in neonatal mice was 
suppressed by capsaicin treatment, which depletes CGRP from sensory nerve endings 
(35). We had confirmed the effects of chemical denervation in the WT mice used in this 
study (Fig. 8E). C-fibers, which contain CGRP in their nerve endings, may be relevant 
to RAMP1-mediated neovascularization. In fact, surgical denervation of primary 
sensory neurons resulted in reduced angiogenesis and lymphangiogenesis (Fig. 8A-D). 
Further, in our previous reports, CGRP enhanced the healing of gastric ulcers, with 
substantial induction of angiogenesis in the ulcer base tissues (13), and recovery from 
hindlimb ischemia induced by the ligation of femoral arteries was augmented by the 
release of CGRP from the sensory nerves (12). In these instances, it is plausible to 
hypothesize that C-fibers were stimulated to release CGRP by proton ions secreted 
from the gastric mucosa or by ischemia, suggesting that the release of CGRP in such 
pathologic settings plays a significant role in enhancing angiogenesis. RAMP1 may be 
an element that is responsible for CGRP released during pathologic processes.  
The functional and morphologic relationships between primary afferent neurons and 
blood vessels in pathologic conditions, such as ischemia and cancer development, are 
poorly understood. However, recent evidence suggests that the physical and 
biochemical interactions between these peripheral components are important in tumor 
biology and cancer-associated pain (36). Angiogenesis is a critical determinant for 
tumor growth, and an angiogenic switch, which allows the tumor to receive an 
adequate blood supply, is activated in the quiescent vasculature around tumors, 
contributing to tumor growth and metastasis, and ultimately decides a patient’s 
prognosis. The neuronal system plays a fundamental role in the maturation of 
primitive embryonic vasculature. Mutations that disrupt peripheral sensory nerves or 
Schwann cells prevent proper arteriogenesis, whereas those that disorganize the 
nerves result in arteries with misrouted axons (37). It is also reported that sensory 
-15- 
 
neurons modulate the expression of arterial markers on ECs via the secretion of VEGF 
164/120. These data suggest that during development, peripheral nerves play a role in 
determining organ-specific patterns of blood vessel branching and arterial maturation 
(38).  
Some neuronal factors, such as Notch, are also reported to contribute to pathologic 
angiogenesis. Specialized ECs called tip cells, which lead and guide sprouting, share 
many features with another guidance structure, the axonal growth cone (39). Axonal 
growth cones and endothelial tip cells both respond to signals originating from the 
same molecular families, such as Slits and Roundabouts, Netrins and UNC5 receptors; 
Semaphorins, Plexins and Neuropilins; and Eph receptors and ephrin ligands. 
Activation of the Notch pathway and VEGF signaling induces angiogenic growth of ECs 
and the selection of tip cells, and Notch signaling is a key pathway that is activated 
during ischemia-induced neovascularization (40). Indeed, Notch signaling regulates 
several steps of the reparative process in ischemic tissues, including sprouting 
angiogenesis, vessel maturation, interaction of vascular cells with leukocytes, and 
skeletal myocyte regeneration. Together with findings in our previous studies, the 
present results suggest that CGRP has a major role in pathologic angiogenesis (11-13). 
Thus, RAMP1 is also a major player in these interactions. Thus, renewed focus should 
be placed on the interactions that occur between the neuronal systems and the 
lymphatic systems in pathologic conditions.  
As discussed above, the findings in the present study indicate that both angiogenesis and 
lymphangiogenesis are enhanced by RAMP1 signaling in wound granulation tissues. 
RAMP1 was not expressed on ECs or lymphatic ECs during neovascularization. RAMP1 
signaling was relevant to the expression of VEGF isoforms in macrophages derived from 
the BM, as tested in RAMP1-/- BM chimeric mice. Unlike AM-null mice, which exhibit 
edema during development, RAMP1-null mice are healthy, with no evidence of edema 
formation. Pathologic lymphangiogenesis was hampered in RAMP1-/- mice, as was 
drainage of interstitial fluids. The findings presented in this study indicate that RAMP1 
signaling holds therapeutic potential for the treatment of pathologic 
angiogenesis/lymphangiogenesis-related conditions. 
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Figure Legends 
 
Figure 1. Reduced RAMP1 mRNA levels and delayed wound healing in RAMP1-/- mice 
A-C) mRNA levels of pro-CGRP (A), CGRP (B), and RAMP1 (C) in DRGs. Data are 
expressed as means ± SEM of 4 mice/group. There was no difference between 2 
groups before wounding (A, B), whereas a marked reduction in RAMP1 mRNA 
levels was seen in RAMP1-/- mice (C).  
D) Time course of wound closure in RAMP1-/- and WT mice. Surgical wounds were 
made on the backs of RAMP1-/- mice and their WT counterparts, and wound closure 
was monitored as described in Materials and Methods. Data are expressed as means 
± SEM of 8 mice/group. *p < 0.05, **p < 0.01 vs. WT mice.  
E) Typical appearance of wounds in RAMP1-/- and WT mice at days 3, 5, and 7. 
Original diameter of the wounds was 6 mm.  
 
Figure 2. Inhibition of wound-induced angiogenesis in RAMP1-/- mice 
Surgical wounds were made on the backs of RAMP1-/- and their WT counterparts, and 
angiogenesis in the wound granulation tissues was monitored as described in Materials 
and Methods.  
A) Double immunostaining of normal tissue in an uninjured lesion (left) and 
granulation tissue (right) from WT mice at day 5 with antibodies against CD31 
(red) and RAMP1 (green). Scale bars = 100 μm.  
B, C) Typical results of HE staining (day 6; B) and CD31 immunostaining (day 2-7; C) 
of wound granulation tissues in RAMP1-/- and WT mice. A reduced number of 
CD31-positive microvessels (brown stains indicated by red arrows) was observed 
in the granulation tissues of RAMP1-/- mice compared with that in WT mice. 
Scale bars = 100 μm.  
D) Changes in microvessel density in granulation tissues at day 2-7. Tissues were 
stained for CD31 and photographed, and microvessels in the wound granulation 
tissues were counted. Microvessel density is expressed as microvessels per square 
millimeter. Data are expressed as means ± SEM from 6 mice/group; significantly 
different from WT mice at day 2-7. *p < 0.05 vs. WT mice.  
E, F) mRNA expression levels of CD31 (E) and VEGF-A (F) in the wound granulation 
tissues of RAMP1-/- and WT mice determined by real-time RT-PCR at days 0, 2, 3, 
5, 7, 10, and 14. Data are expressed as means ± SEM of 6 mice/group. *p < 0.05, 
**p < 0.01 vs. WT mice. 
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Figure 3. Effects of CGRP on the expression of VEGF-A, VEGF-C and VEGF-D in 
peritoneal thioglycolate-elicited macrophages and mouse fibroblast L929 cells 
A) Double immunostaining of granulation tissue from WT mice at day 7 with antibodies 
against CD11b (red) and RAMP1 (green). Scale bar = 10 μm. 
B) Double immunostaining of granulation tissue from WT mice at day 7 with antibodies 
against S100A4 (red) and RAMP1 (green). Scale bar = 20 μm.  
C-E) Macrophages isolated from WT and RAMP1-/- mice were treated with CGRP 
agonists, and the mRNA levels of VEGF-A (C), VEGF-C (D), and VEGF-D (E) 
were determined 4 h after incubation. Real-time quantitative RT-PCR assays 
were used to assess mRNA expression. Data are expressed as means ± SEM of 3 
independent experiments. *p < 0.05 vs. vehicle.  
F-H) Mouse fibroblasts, L929 cells were treated with CGRP agonists for 4 h. mRNA 
levels of VEGF-A (F), VEGF-C (G), and VEGF-D (H) were determined by real-time 
quantitative RT-PCR assays. Data are expressed as means ± SEM of 3 
independent experiments. CGRP agonists did not significantly increase VEGF-A, 
-C or -D production in L929 cells. *p < 0.05 vs. vehicle. 
 
Figure 4. Inhibition of wound-induced lymphangiogenesis in RAMP1-/- mice  
Surgical wounds were made on the backs of RAMP1-/- and their WT counterparts, and 
lymphangiogenesis in the wound granulation tissues was assessed, as described in 
Materials and Methods.  
A) Double immunostaining of granulation tissues from WT mice at day 7 with 
antibodies against LYVE-1 (red) and RAMP1 (green). Scale bars = 50 μm.  
B, C) Typical results of HE staining (day 7; B) and LYVE-1 immunostaining (day 3, 5, 6, 
7, and 10; C) in the wound granulation tissues in RAMP1-/- and WT mice. A lesser 
number of LYVE-1-positive microvessels (brown stains indicated by red arrows) 
was observed in the granulation tissues of RAMP1-/- mice than in WT mice. Scale 
bars = 100 μm.  
D) Changes in lymphatic vessel density in the granulation tissues at days 3, 5, 6, 7, and 
10. Tissues were stained for LYVE-1 and photographed, and lymphatic vessels in 
the wound granulation tissues were counted. Lymphatic vessel density is expressed 
per square millimeter. Data are expressed as means ± SEM of 6 mice/group, 
significantly different from WT mice at days 6, 7, and 10. *p < 0.05 vs. WT mice.  
E, F) mRNA expression levels of VEGF-C (E) and VEGFR-3 (F) in the wound 
granulation tissues of RAMP1-/- and WT mice, determined by real-time RT-PCR 
at days 0, 2, 3, 5, 7, 10, and 14. Data are expressed as means ± SEM of 6 
mice/group. *p < 0.05, and **p < 0.01 vs. WT mice.  
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G) Fluorescence images of axillary lymph nodes 2 h after injection of 200 μl of 3% 
fluorescein isothiocyanate–dextran into the wounds on day 7 with a microsyringe. 
Scale bars = 5 mm. H) Quantification of the fluorescence of the extracted dye 
indicated that drainage from the wound area to the regional lymph nodes was 
reduced in RAMP1-/- mice (n = 5 for RAMP1-/-; n = 10 for WT).  
 
Figure 5. Time course of wound healing, angiogenesis and lymphangiogenesis in mice 
with BM cells transplanted from RAMP1-/- mice  
A lethal dose of radiation was administered to WT mice and BM cells from either WT 
mice or RAMP1-/- mice were injected into the tail vein (WT→WT or RAMP1-/-→WT). 
Surgical wounds were made on the backs of the mice, and wound closure was assessed 
as described in Materials and Methods.  
A) Time course of wound closure in the WT mice transplanted with BM cells from 
RAMP1-/- or WT mice. Data are expressed as means ± SEM from 8 mice/group. *p < 
0.05 and **p < 0.01 vs. WT mice.  
B) Typical results of CD31 immunostaining of the wound granulation tissues in the WT 
mice with BM cells transplanted from RAMP1-/- or WT mice at day 3. A lesser 
number of CD31-positive microvessels (brown staining indicated by red arrows) was 
observed in the granulation tissues of RAMP1-/-→WT mice than in the WT→WT 
mice. Scale bars = 100 μm.  
C) Microvessel density in granulation tissues on day 3. Data are expressed as means ± 
SEM from 6 mice/group, significantly different from WT→WT mice. **p < 0.01 vs. 
WT→WT mice.  
D) Typical results of LYVE-1 immunostaining of the wound granulation tissues of WT 
mice with BM cells transplanted from either RAMP1-/- or WT mice at day 7. A lower 
number of LYVE-1-positive microvessels (brown staining indicated by red arrows) 
was observed in the granulation tissues of RAMP1-/-→WT mice than in WT→WT 
mice. Scale bars = 100 μm. E) Lymphatic vessel density in granulation tissues on 
day 7. Data are expressed as means ± SEM from 6 mice/group, significantly 
different from WT→WT mice. **p < 0.01 vs. WT→WT mice. 
 
Figure 6. Temporal changes in the expressions of growth factors in wound granulation 
tissues 
mRNA levels of EGF (A), TGFβ (B), bFGF (C), and CTGF (D) in wound granulation 
tissues in RAMP1-/- and WT determined by real-time RT-PCR at day 0, 2, 3, 5, 7, 10, 
and 14. Data are expressed as the means ± SEM from four mice/group. *p < 0.05 vs. 
WT mice. 
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Figure 7. Representative immunohistochemical/immunofluorescence staining of 
RAMP1, CD11b and S100A4 in wound granulation tissues in BM chimera mice 
A, B) A lethal dose of radiation was administered to WT mice and BM cells from either 
WT mice or RAMP1-/- mice were injected into the tail vein (A; WT→WT or B; 
RAMP1-/-→WT). Surgical wounds were made on the backs of the mice, and 7 days 
after wounding, wound granulation tissues were stained with antibodies against 
RAMP1 (brown). Counter stain was performed with Hematoxylin. Images are 
representative of three independent samples. Scale bar = 50 μm.  
C, D, E) Seven days after wounding, wound granulation tissues in GFP BM chimera 
mice were stained with antibodies against RAMP1 (C; red), CD11b (D; red) or 
S1004A (E; red), and images were merged. Counter stain was performed with 
DAPI. Images are representative of three independent samples. Scale bar = 
10 μm.  
 
Figure 8. Effects of surgical denervation and chemical denervation on angiogenesis and  
lymphangiogenesis in wound granulation tissues 
A) Typical results of CD31 immunostaining in wound granulation tissues made on the  
hind limbs in mice surgically denervated and in sham operated mice. Results from 
WT mice 7 days after wounding were shown. Reduced numbers of CD31-positive 
microvessels (brown stains indicated by red arrows) were observed in the 
granulation tissues in denervated WT mice. Scale bars = 100 μm.  
B) Microvessel density in granulation tissues at day 7 in surgically denervated mice.  
Tissues were stained for CD31, and microvessel density in the wound granulation 
tissues was counted. Microvessel density was expressed as microvessels per mm2. 
Data are expressed as means ± SEM from 6 mice/group; significantly different 
from WT mice at day 7 (**p < 0.01 vs. sham mice). 
C) Typical results of LYVE-1 immunostaining in the wound granulation tissues made  
on the hind limbs in mice surgically denervated mice. Results from WT mice 7 days 
after wounding were shown. Reduced numbers of LYVE-1-positive microvessels 
(brown stains indicated by red arrows) were observed in the granulation tissues in 
denervated WT mice. Scale bars = 100 μm. 
D) Lymphatic vessel density in granulation tissues at day 7 in surgically denervated  
mice. Tissues stained were for LYVE-1 and lymphatic vessels in the wound 
granulation tissues were counted. Density was expressed as microvessels per mm2. 
Data are expressed as means ± SEM from 6 mice/ group; significantly different 
from sham operated mice at day 7 (*p < 0.05 vs. sham mice). 
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E) Effect of chemical denervation on wound healing. Healing process (% of original  
wound size) in capsaicin treated WT mice were compared with vehicle treated mice. 
Data are expressed as means ±  SEM from sixteen mice/group; significantly 
different from vehicle treated mice at day 1, 4 and 7 (**p < 0.01 vs. vehicle treated 
mice). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
